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Dermatofibrosarcoma protuberans is a locally aggressive mesenchymal neoplasm. It usually presents as an
indurated plaque that protrudes above the surface of the skin. Some patients have clinically persistent plaques that
might be atrophic. The atrophic variant of dermatofibrosarcoma protuberans may be confused with some common
skin diseases with atrophic appearance. We reported a 40-year-old woman who had a 10-year history of an atrophic
dermatofibrosarcoma protuberans. Molecular analysis showed a fusion between COL1A1 exon 31 to exon 2 of
PDGFB. The lesion was totally excised, with negative margins of the resection demonstrated by CD34
immunostaining. To our knowledge, this is the second case of atrophic dermatofibrosarcoma protuberans
confirmed by detection of COL1A1-PDGFB fusion gene. This appears to be the first report of a fusion between
COL1A1 exon 31 to exon 2 of PDGFB in atrophic dermatofibrosarcoma protuberans.
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Dermatofibrosarcoma protuberans is a locally aggressive
mesenchymal neoplasm [1]. The lesions of this tumor
usually present as indurated plaques that protrude above
the surface of the skin [1,2]. The atrophic variant is a
rare form of the tumor [3-5]. Translocation of t(17;22)
(q22;q13) is the cytogenetic features of dermatofibrosar-
coma protuberans [6]. As a consequence of this chromo-
somal rearrangement, fusion of the collagen type I α 1
(COL1A1) gene on 17q, with the platelet-derived growth
factor β-chain (PDGFB) gene on 22q, is detected [6].
The fusion gene has been detected in several unusual
variants of dermatofibrosarcoma protuberans (pigmen-
ted variant, giant cell fibroblastoma, and granular vari-
ant) [1,6]. The fusion gene has been detected only in
one case of atrophic variant of dermatofibrosarcoma
protuberans [7]. Here we report a case of atrophic* Correspondence: fanghongzy@sina.com
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reproduction in any medium, provided the ordermatofibrosarcoma protuberans confirmed by detec-
tion of the COL1A1-PDGFB fusion gene. The gene fu-
sion between COL1A1 exon 31 to exon 2 of PDGFB
observed in our patient is firstly reported in atrophic
dermatofibrosarcoma protuberans.Case presentation
In Apr 2010, a 40-year-old Chinese woman presented
to our department of dermatology with a 10-year his-
tory of an asymptomatic, slowly enlarging rash located
on the right pars lumbalis. She was otherwise healthy
and had no systemic symptoms. The patient had no
personal or family history of cancer. There was no his-
tory of trauma to the area. Physical examination
showed a smooth-surfaced, round, depressed plaque on
the right lumbalis area (Figure 1). On palpation the
rash was atrophic with no induration. Clinical diagnoses
of morphea and morpheaform basal cell carcinoma
were suspected. The lesion was totally excised. Histo-
pathology examination revealed extensive areas of
tumor cell growth in the dermis and subcutaneousd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A smooth-surfaced, round, depressed plaque on the
right pars lumbalis area.
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and had poorly defined margins. The tumor was com-
posed of monomorphic spindle cells that aligned horizon-
tally to the epidermis (Figure 2A). The nuclei were thin,
elongated and often wavy, with little pleomorphism
(Figure 2B). The tumor tissue contained no mucin and
melanins. The spindle cells were immunohistochemically
positive for CD34 (Figure 3) and vimentin, and negative
for factor XIIIa, smooth muscle actin, and CD68. The sur-
gical margins were negative demonstrated by CD34
immunostaining. RNA was extracted from the formalin-
fixed, paraffin embedded surgical specimen for COL1A1/
PDGFB chimeric transcripts analysis, by multiplex reverse
transcription polymerase chain reaction (RT-PCR) assay.
Sequencing of the multiplex RT-PCR amplification prod-
uct revealed a fusion of exon 31 of COL1A1, to exon 2 of
PDGFB (Figure 4). A diagnosis of atrophic dermatofibro-
sarcoma protuberans was established. The patient
remains without evidence of local recurrence after 2
years of follow-up.Figure 2 (A) Biopsy revealed a monomorphic spindle cell proliferation
aligned horizontally to the epidermis section (hematoxylin-eosin, orig
thin, elongated and often wavy, with little pleomorphism (hematoxylDiscussion
Dermatofibrosarcoma protuberans is a locally aggressive
mesenchymal neoplasm with an intermediate grade and
a high rate of local recurrence [1,6]. The incidence has
been reported between 0.8–5.0 cases per 1 million per-
sons per year. Men and women are equally affected. Der-
matofibrosarcoma protuberans most commonly occurs
in adults between the ages of 20 and 50, and are most
commonly located on the trunk and the proximal ex-
tremities [1,2].
Dermatofibrosarcoma protuberans usually appears as
an indurated, exophytic, asymptomatic, flesh-to-red/
brown plaque that protrude above the surface of the skin
[1]. These characteristic lesions are usually not difficult
to diagnose clinically. However, the often slow clinical
evolution of dermatofibrosarcoma protuberans is typi-
fied by an initial plaque stage and a later nodular stage
[8]. Some patients have clinically persistent plaques that
might be atrophic, as in our patient [5]. These atrophic
plaques are believed to represent early lesions in the
course of dermatofibrosarcoma protuberans [8,9], and
have rarely been reported and characterized in detail.
Given the typical ‘protuberant’ morphology, the diagno-
sis of atrophic lesions of dermatofibrosarcoma protuber-
ans is frequently delayed [5,8].
The atrophic variant of this tumor is often clinically con-
fused with common conditions characterized by atrophy or
sclerosis, such as morphea, atrophic scar, morpheaform
basal cell carcinoma, lipoatrophy, idiopathic atrophoderma,
anetoderma, atrophic dermatofibroma, neurofibroma, re-
solving panniculitis, steroid atrophy, and medallion-like
dermal dendrocyte hamartoma [3-5,8,10,11].
Histopathologically, dermatofibrosarcoma protuberans
tumor cells are composed of densely packed, mono-
morphous spindle cells arranged in a storiform or
whorled pattern, frequently infiltrating into subcutis and
extending laterally into the surrounding dermis [1]. It
may also involve the fascia, muscle and bone [6]. Cellsin the dermis and subcutaneous fat, with the spindle cells
inal magnification: ×100). (B) The nuclei of the spindle cells were
in-eosin, original magnification: ×400).
Figure 3 The spindle cells were immunohistochemically positive for CD34 (CD34 stain; original magnifications: A, ×40, B, × 400).
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There are some variants of dermatofibrosarcoma protu-
berans, including pigmented variant (Bednar tumor),
congenital variant, giant cell fibroblastoma, atrophic
variant, and fibrosarcomatous variant. The former four
variant typically behave similarly to the classic type.
However, the fibrosarcomatous variant is more aggres-
sive, with a high propensity for metastasis [1,6].
Histopathologically, dermatofibrosarcoma protuberans
should be differentiated from other cutaneous spindle
cell tumors, including dermatofibroma, fibrosarcoma,Figure 4 Detection of surgical specimen revealed a fusion of
collagen 1 α1 gene (COL1A1) exon 31, to exon 2 of the platelet
derived growth factor B gene (PDGFB).malignant fibrohistocytoma, atypical fibroxanthoma,
desmoplastic melanoma, keloid, Kaposi sarcoma, and
solitary fibrous tumor [1,12,13]. Immunostains are help-
ful to differentiate dermatofibrosarcoma protuberans
from other fibrohistiocytic neoplasms. Typically, cells of
dermatofibrosarcoma protuberans are diffusely labeled
with CD34 and are negative for factor XIIIa [1,5], distin-
guishing it from analogous neoplasms. The converse is
true for most cases of dermatofibroma. Dermatofibrosar-
coma protuberans is negative for CD68, allowing differ-
entiation from atypical fibroxanthoma and malignant
fibrohistocytoma, and is also typically negative for S100,
helping distinguish it from desmoplastic melanoma [14].
Solitary fibrous tumor also consists of bland spindle
cells but the tumor is well circumscribed. Similar to that
in dermatofibrosarcoma protuberans, solitary fibrous
tumor commonly labeled with CD34 and vimentin.
However spindle cells in solitary fibrous tumor also ex-
press CD99 and bcl-2, which are negative for dermatofi-
brosarcoma protuberans [13].
Kaposi sarcoma is a vascular tumor with low-grade
malignant potential. The tumor often composed of spin-
dle cells, with slit-like vascular channels containing ery-
throcytes. The spindle cells not only express CD34 but
also are immunoreactive for CD31 and human herpes
virus 8 [12].
Medallion-like dermal dendrocyte hamartoma is a
newly described and rare entity [15]. This tumor is be-
nign. However, it shows morphologic, histological, and
immunohistochemistrial overlap with atrophic dermato-
fibrosarcoma protuberans [15,16]. The lesions of
medallion-like dermal dendrocyte hamartoma are round,
solitary, well-demarcated, oval or triangular erythema-
tous and atrophic plaques of several centimetres in
diameter [15,16]. They are histologically characterized
by a spindle cell proliferation in the dermis and in the
subcutaneous fat. Furthermore, immunochemical stain-
ing for CD34 and factor XIIIa is usually positive in the
hamartoma. Molecular testing is an important tool to
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sarcoma protuberans, as there is not known rearrange-
ments associated with hamartoma [15-17].
Nearly all dermatofibrosarcoma protuberans carry a
t(17;22)(q22;q13) chromosomal translocation, which
fuses the COL1A1 gene on chromosome 17 to PDGFB
on chromosome 22, and result in a chimeric COL1A1-
PDGFB protein [18]. The translocation can be identified
by fluorescence in situ hybridization, or RT-PCR, and
confirmed by sequencing of the chimeric COL1A1/
PDGFB. Llombart et al. reported the first case of atro-
phic dermatofibrosarcoma protuberans that was con-
firmed by COL1A1-PDGFB fusion gene detection [7].
To our knowledge, this is the second case of atrophic
dermatofibrosarcoma protuberans whose diagnosis was
confirmed by detection of the fusion gene. COL1A1
encodes the α-chains of type 1 collagen, and PDGFB
codes for the β-chain of platelet-derived growth factor.
The latter is a potent mitogen that acts on a variety of
cells. After gene fusion of COL1A and PDGFB, the in-
hibitory regulatory element of PDGFB is replaced by
COL1A1, which allows for producing high levels of the
chimeric COL1A1-PDGFB mRNA. PDGFB is cleaved
from the COL1A1-PDFGB protein and the cleaved
PDGFB turns to stimulate cells in an autocrine fashion,
leading to malignant transformation [18]. Fusion of
COL1A1 exon 31 to exon 2 of PDGFB, as seen in our
patient, was not reported previously in atrophic derma-
tofibrosarcoma protuberans. However, it has been postu-
lated that the different types of fusion between COL1A1
and PDGFB are not related with the clinical or histo-
logical features [7,19].
The standard treatment of the sarcoma is local exci-
sion with wide margins. Mohs surgery allows complete
examination of the margins while sparing the maximum
amount of healthy tissue [20-23]. Surgical treatment,
however, is not always possible [20]. Imatinib mesylate,
targeting platelet-derived growth factor receptor beta,
has clinical potential in dermatofibrosarcoma protuber-
ans. It has been demonstrated that imatinib mesylate
inhibits the tyrosine kinase activity of PDGF-BB and
causes apoptosis of the dermatofibrosarcoma protuber-
ans cells [24,25]. Clinical trials demonstrated that imati-
nib has profound antitumor effects in advanced
dermatofibrosarcoma protuberans harboring t(17;22)
(q22;q13) [25-28].Conclusion
In conclusion, we report a case of atrophic dermatofi-
brosarcoma protuberans, which clinically masquerades
as various atrophic cutaneous disorders. This variant is
believed to represent an early stage of this lesion. This
entity can be differentiated from other clinically similarlesions by histology, immunohistochemistry, and mo-
lecular genetics.
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